Today’s the day! The H-SPAN Summit D.C. agenda is officially LIVE!
Check out our incredible lineup of sessions and speakers here: a4li.org/h-span-summit-dc/
Let us know who you’re most excited to see by commenting below!
For the next week, get 20% off a ticket using promo code: HEALTHSPAN
Save the Date: The fourth annual H-SPAN Summit D.C. is coming June 14-15, 2027!
We’re excited to return to the Georgetown University Capitol Campus, once again partnering with the Georgetown University Center for Healthy Aging!
Building on last year's momentum, we invite leaders at the forefront of aging biology to help advance longevity science policy with the shared mission of making healthy aging a national priority.
Registration, sponsorship opportunities, and the full program agenda are coming soon. Follow along for updates!
Read the full press release here: a4li.org/wp-content/uploads/…
Aging and Longevity Added to Focus Areas of FDA Regulatory Science
The @US_FDA’s Office of Regulatory and Emerging Science just released their Broad Agency Announcement for Fiscal Year 2027 and it includes aging and longevity as a focus area!
The agency is actively looking to fund external researchers, biotech innovators, and academic labs to solve the longevity field's biggest regulatory bottlenecks, including:
✅ Validating aging biomarkers with the goal of advancing candidates toward validated or reasonably likely surrogate endpoint status under the FDA-NIH BEST framework.
✅ Developing and modernizing clinical trial frameworks for aging related indications, including multimorbidity prevention frameworks and risk-enrichment strategies using validated aging biomarkers.
✅ Generating high-quality, longitudinal data-sets to assess the relationship between aging-related biomarkers (and its heterogeneity) and later clinical outcomes.
We want our longevity industry to succeed, so we must work together to build the tools, standards, and approaches needed for the FDA to evaluate the safety and efficacy of products that target the biology of aging.
Aging and longevity ARE public health initiatives and they perfectly align with the FDA’s 4 Public Health Pillars:
1️⃣ Innovation and Global Leadership
2️⃣ Advancing National Health Security
3️⃣ Increasing Access to Affordable Medicines & Medical Products
4️⃣ Preventing Chronic Disease and Promoting Wellness in America
So if you are building in this space, please apply! This is the regulatory and funding signal we have been waiting for. The deadline to submit for FY27 consideration is January 22, 2027.
🔗Explore the extramural R&D program and see how BAA funding works here: fda.gov/science-research/adv…
🧬 The Faster Clinical Trials Act Has Officially Been Introduced!
In September, we shared that Rep. @JakeAuch (D-MA) was developing legislation to bring clinical trials into routine patient care. Now, he and Energy and Commerce Health Subcommittee Chairman Morgan Griffith (R-VA) have officially introduced the bipartisan Faster Clinical Trials Act.
The legislation would establish a new FDA Center for Clinical Trial Innovation and make it easier to conduct research in the places patients already receive care, including primary care offices, community clinics, virtual visits, and even their own homes.
For longevity science, this has important implications. Older adults experience a disproportionate burden of chronic disease, yet remain underrepresented in clinical research. In NIH-funded cancer studies, adults 65 and older accounted for just 26% of participants, despite representing 56% of new cancer cases.
By integrating research into routine care and allowing Medicare to cover routine clinical trial costs, the legislation could help address this gap, making it easier for older adults to participate in the research that may ultimately benefit them.
📖 Read the full press release here: auchincloss.house.gov/media/…
At A4LI, we believe advancing longevity science means not only developing new therapies, but ensuring the people who stand to benefit most are represented in the research that brings those therapies to patients. We're grateful to Rep. Auchincloss and Chairman Griffith for their bipartisan leadership.
Warmest congratulations to our partners at @Georgetown University and the @BuckInstitute for Research on Aging on securing funding for the BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) program.
Go Team SEEDS!
Excited to co-lead SEEDS with @Georgetown, supported by @ARPA_H!
This ambitious collaboration aims to predict harmful protein changes linked to disease.
More Monday on the science, researchers and partners!
#BuckInstitute#SEEDS#Livebetterlonger
Some of the biggest challenges in human health require new ways of thinking.
ARPA-H is looking for the scientists, engineers, physicians, and other technical experts with bold ideas for tackling problems that have remained out of reach through conventional approaches.
Program Managers at ARPA-H have the opportunity to develop and lead ambitious programs, bring together multidisciplinary teams, and move transformative ideas toward real-world health outcomes.
For those with the expertise and a vision for what could be possible, this is an opportunity to turn that vision into action.
ARPA-H is looking for health visionaries.
Deeply technical. Big vision.
Stuck in a role that’s too small for what you want to build?
Bring us your best ideas. Apply to be a Program Manager 🚀
linkedin.com/jobs/view/44661…
Highly positive panel on longevity trials at ARDD:
Lowell Zeta (chief of staff) says longevity is a priority for the current FDA.
There's now a point person for longevity trial design: Justin Penzenstadler (reviewer on GLP1s).
Steven Kozlowski (chief scientist) working on guidance and tech specs, to be released first half of next year.
Justin recommends the field forma precompetitive consortium for which biomarkers, how to include in trials. And to talk to regulators regularly.
Good writing and any improvement in this area will go a long way for patients! BUT its central diagnosis (that the science is largely ready and development is now the bottleneck) fits oncology far better than neurodegeneration.🧠
We have not solved the upstream science in Alzheimer's or Parkinson's. We have few (I'd argue, no) therapies for their root causes. These diseases unfold for years or decades before before they become clinically detectable, often through very noisy readouts. So even if you had a potential treatment at hand, it could take a long, looong time before you'd be able to detect an improvement. Faster Ph1 trials are not the (primary) solution for fixing this fundamentally broken feedback loop.
Instead, we'd need better experimental systems, biomarkers and longitudinal data that lets us learn much faster from the bench to patients. Case in point:
For years, critics have labeled Capitol Hill a "gerontocracy." The AP News Congressional Retirements Tracker shows a massive wave of lawmakers heading for the exits this election cycle, while underscoring a broader trend: Congress has steadily aged over the last century. While dozens of members are not seeking reelection to their current seats, many aren't stepping away from public life entirely, opting instead to pursue governorships or Senate seats. As a new generation of leaders steps up, we’ll be watching to see how the demographic landscape of Congress evolves.
Nonetheless, the timing and opportunity for aging biology and longevity biotechnology have never been more ripe. At A4LI, we continue to champion this vision by advocating for policies that accelerate next-generation disease-modifying therapies. By pairing longer lifespans with vibrant healthspans, we ensure everyone has the energy to pursue what they love and the opportunity to pivot careers at any stage of life.
Source: apnews.com/projects/2026-con…
Had a great time chatting with Christina about her journey in science and her current work looking at senescence in the gut in non-human primates at @WakeForest!
This week on A4LI’s Scientist Spotlight, we speak with Dr. Christina Stevens, a fourth-year graduate student in Dr. Kylie Kavanagh's lab at Wake Forest University School of Medicine.
In this episode, we discuss her background in veterinary medicine, how she has applied that to aging research, and what has driven her to pursue a career in academia.
Listen to the full episode here: a4li.org/podcast/scientist-s…
IT'S OUT. 🎉
FRONTIERS OF LONGEVITY SCIENCE @SpringerNature
Leading scientists, clinicians, and entrepreneurs on where the field stands, and where it will go.
Science today. Longevity tomorrow. 🚀
Like and repost to help it travel!👇👨⚕️
🔗linkedin.com/posts/agingdoc_…
What role should public policy play in extending healthy human lifespan?
Our Founder, @dullunlivin, recently joined the @LongevityTech UNLOCKED podcast to discuss why advancing longevity science requires more than scientific breakthroughs. It also requires policies that help bring those breakthroughs to the people who need them.
The conversation explores the growing momentum behind longevity policy, the challenges that remain, and why now is the time to rethink how governments approach healthy aging.
🎥 You can watch the full interview here: youtube.com/watch?v=LCl0oQ5k…
🧠 Longevity Fact of the Week
12.4 years.
That's the average gap between lifespan and healthspan in the United States.
In other words, the average American spends more than 12 years living with disease or disability before the end of life.
While we have made remarkable progress in helping people live longer, the next challenge is helping people stay healthier for longer.
At A4LI, we have made it our mission to advance policies that accelerate the development of therapies targeting the biology of aging, with the goal of extending not just lifespan, but healthspan as well.
📖 Learn more about the research behind the healthspan gap here: pmc.ncbi.nlm.nih.gov/article…
Last week, leaders in academia, longevity biotech, and policymakers came together in Washington, D.C. for our largest H-SPAN Summit to date.
In an article for @LongevityTech, A4LI Vice President of Communications & Partnerships Dr. Brenda Eap reflects on this year’s Summit, from discussions with federal regulators and Members of Congress to the policy priorities that will shape the future of healthy longevity.
You can read the full article here: longevity.technology/news/us…